explore -WSS

explore

author：hotspot 2025-09-30 17:44:42 - browse：73651

David Sabatini at home — David Sabatini posed at his home in Cambridge in 2022. Craig F. Walker/Boston Globe

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his lofty positions after being accused of violating sexual harassment policies in 2021, is rejoining the Boston scientific community as head of a research group at a new laboratory under the umbrella of a Czech-based scientific institute.

Sabatini, who has denied harassing anyone and filed litigation over the claims, has been working since last October in a senior research position at the Institute of Organic Chemistry and Biochemistry, in the Czech Republic capital of Prague, investigating scientific questions in the areas of cell growth and metabolism, similar to his past research at Whitehead.

The Czech institute, known as IOCB Prague, is realizing a long-held ambition to expand into the Boston biotech hub, confirmed the institute’s director, Jan Konvalinka.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Case highlights the risks of experimental stem cell therapy

WSS

Grail is spending more than ever lobbying Congress

Listen: Biogen's messy board & Laronde's data problem

PhRMA sues HHS over Medicare drug price negotiation

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Doctor appointment wait times are getting worse

Wearables generate powerful data but its not useful to doctors, yet

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Duchenne breakthrough therapy leaves behind pioneering families

Addiction experts warn against a second 'war on drugs'

Wildfire smoke exposes gaps in outdoor worker protections

Listen: PBM conflicts, RSV vaccines, & the future of flu season

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Grail is spending more than ever lobbying Congress

Psychedelics group wrestles with new pharma identity

When is a doctor not a doctor? Try when patients address women doctors

Medicare proposal to cover medical devices draws a mixed reaction

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

entertainment

With measles on the rise, a personal story of a devastating disease

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Listen: Biogen's messy board & Laronde's data problem

7 people shot in DC, police say

Community addresses injustice for Long Island mothers

These geoengineering technologies could help combat the climate crisis, scientists say

hotspot

knowledge

focus

focus